MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Current Assets
All assets expected to be converted to cash or used up within one year.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Current Assets · Q3 FY2026 · quarter ended Sep 2026
Total current assets rises 24.0% from a year ago
Total current assets stood at $492.76M at the end of Q3 FY2026, up 24.0% from a year earlier and up 15.2% from the prior quarter. Over 3 fiscal years it compounded at +105.1% a year.
Context
- Total current assets amounted to 98.4% of total assets at the end of Q3 FY2026, down 0.9 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +24.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 381.54M USD
- Year-over-year change
- +42.7%
- 3-year CAGR
- +105.1%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 381.54M | +42.7% |
| FY2024 | 2024-12-31 | 267.29M | +220.2% |
| FY2023 | 2023-12-31 | 83.47M | +88.8% |
| FY2022 | 2022-12-31 | 44.21M | — |
Total Current Assets vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +24.0% is the 4th highest of 8, against a peer median of +3.7%.
- Total current assets amounts to 98.4% of total assets for MBX, versus a peer median of 85.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €1.59B EUR | +55.9% | +6.3% | 65.4% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $929.17M USD | — | — | 76.7% |
| Jun 2026 | $517.56M USD | -37.4% | +62.4% | 99.2% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $492.76M USD | +24.0% | +105.1% | 98.4% |
| Sep 2026 | $419.36M USD | -15.2% | +9.6% | 94.6% | |
| Mar 2026 | $334.68M USD | +115.6% | +13.0% | 99.7% | |
| Mar 2026 | $251.68M USD | +53.9% | +8.8% | 64.2% | |
| Mar 2026 | $68.15M USD | -48.2% | -5.3% | 25.3% | |
| Mar 2026 | $46.32M USD | +3.7% | -21.0% | 99.9% | |
| Peer median (excluding MBX) | — | +3.7% | +8.8% | 85.7% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.